Drug intelligence / Profile preview

ADVC005

Development stage: Preclinical
Lead developer: Advancell
Modality: Small Molecules

Overview

ADVC005 is a chemical drug candidate initially developed by AdvanCell Isotopes. It is in preclinical development for the treatment of neoplasms, with a primary focus on prostatic cancer (prostate cancer). The drug is being investigated for its potential use in urogenital diseases and cancers, but specific details regarding its mechanism of action, molecular target(s), or chemical structure have not been disclosed publicly as of June 2025. No clinical trial results or regulatory approvals are available at this time[1][3].

Beyond the preview

Go deeper on ADVC005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADVC005.

Explore the full profile